爱唯医学网 | 资讯 | 期刊 | 血液病学学术中心
登录 | 注册
经IMW授权,由西安杨森制药有限公司学术赞助,爱唯医学网(www.Elseviermed.cn)引进了2015年IMW会议课程,总计61套中英文双语在线课程,61套课件概要,同时邀请到中国血液肿瘤领域知名专家针对热门课程进行点评。同时所有课程均可以在目前主流移动终端(iPad,iPhone以及大部分Andriod终端)顺利播放,方便您随时随地学习骨髓瘤领域的最前沿信息。
Biomarker to change Therapy MRD/Imaging vs FISH/Age -‐ in Favor of MRD/Imaging 改变治疗的生物标志: 微小残留病/影像学 vs FISH/年龄-赞成前者
Biomarker to change Therapy MRD/Imaging vs FISH/Age -‐ in Favor of FISH/Age 改变治疗的生物标志: 微小残留病/影像学 vs FISH/年龄-赞成后者
New Diagnostic Criteria for Multiple Myeloma 多发性骨髓瘤的新诊断标准
Flow Cytometry for Minimal Residual Disease 流式细胞术用于微小残留病检测
Next Generation Sequencing for Minimal Residual Disease 下一代测序用于微小残留病检测
Imaging Techniques 影像学技术
Risk Assessment and Stratification 风险评估和分层
Geriatric Assessment and Stratification 老年患者评估和分层
Smoldering Multiple Myeloma 冒烟型多发性骨髓瘤
OP-001 A Meta-Analysis Investigating the Impact of Minimal Residual Disease (MRD) Status on Survival Outcomes in Patients with Multiple Myeloma (MM) who Achieve Complete Response (CR) OP-001 获得完全缓解的多发性骨髓瘤患者中微小残留病状态对生存结局影响的荟萃分析研究
The Vk*MYC mouse model to study drug and immunotherapy response and resistance 使用Vk*MYC 小鼠模型研究药物、免疫疗法应答和抵抗
Multiple Myeloma Biological Pathways 多发性骨髓瘤生物学通路
Multiple Myeloma and the bone marrow niche 多发性骨髓瘤和骨髓微环境
Next Generation Sequencing 下一代测序
Gene Expression Profile 基因表达谱
SNP/microRNA SNP/microRNA
RS-001 Hedgehog Pathway over Expression Identifies Myeloma Patients with worse Prognosis RS-001 Hedgehog通路过表达识别预后较差的骨髓瘤患者
RS-002 Preclinical Analysis of Feasibility and Efficacy of CS1 Directed CAR T cell Therapy in Multiple Myeloma in the Autologous Setting RS-002 CS 1定向CAR-T细胞疗法用于自体同源移植条件下多发性骨髓瘤患者的可行性和有效性临床前分析
RS-003 Carfilzomib and Dexamethasone in Untreated Symptomatic Multiple Myeloma RS-003 卡非佐米和地塞米松治疗未经治疗的症状性多发性骨髓瘤
RS-004 Ribosomal Dysfunction in AL Amyloidosis: Gene Expression Profile Meta-Analysis RS-004 AL淀粉样变性中的核糖体功能障碍:基因表达谱荟萃分析
Optimal Consolidation Therapy 优化的巩固治疗
Transplant Eligible Maintenance 适合移植患者的维持治疗
Ongoing Studies/Open Questions in America, Sergio A. Giralt 美国正在进行的研究及开放式问题(Sergio A. Giralt)
Ongoing Studies/Open Questions in Europe 欧洲正在进行的研究及开放式问题(Roman Hájek)
Ongoing Studies/Open Questions in Asia Pacific 亚太地区正在进行的研究及开放式问题(侯健)
Debate -‐ Change Therapy for High/Low Risk Patients -‐ Yes 争论-高危/低危患者改变治疗-是
Debate -‐ Change Therapy for High/Low Risk Patients -‐ No 争论-高危/低危患者改变治疗-不
Optimal Therapy for Fit Elderly Patients 身体状况良好的老年患者的最佳治疗
Optimal Therapy for Unfit Elderly Patients 身体状况较差的老年患者的最佳治疗
Ongoing Studies/Open Questions in America 美国正在进行的研究及开放式问题(Morie A. Gertz)
Ongoing Studies/Open Questions in Europe 欧洲正在进行的研究及开放式问题(Monika Engelhardt)
Ongoing Studies/Open Questions in Asia Pacific 亚太地区正在进行的研究及开放式问题(Tadao Ishida )
How I treat Relapsed/Refractory Multiple Myeloma, Sequence Strategy,Patient Selection 我如何治疗难治/复发性多发性骨髓瘤,战略次序,患者选择
How I treat Refractory Disease and Extramedullary Disease 我如何治疗难治性疾病和髓外疾病
How I treat Serious Adverse Events 我如何处理严重的不良事件
How I use Bone Support 我如何使用骨支撑
How I use Supportive Care and Palliation 我如何使用支持疗法和姑息治疗
SLAMF7 and combinational monoclonal antibodies therapy SLAMF7 组合单抗疗法
CD38, novel monoclonal antibodies targets, immunotoxin CD38,新单克隆抗体靶点,免疫毒素
CAR-‐T CAR-T
Bispecific Monoclonal Antibodies 双特异性单抗
Significance of Allogeneic Stem Cell Transplantation 同种异体干细胞移植的重要性
Selective HDAC Inhibitor 选择性组蛋白去乙酰化酶抑制剂
Inhibitors (KPT – KSP) 抑制剂(KPT – KSP)
Inhibitors (BCL2 -‐ MCL1 -‐ CDK) 抑制剂(BCL2 - MCL1 - CDK)
Targeting Oncogenic Pathways in Myeloma (MEK-‐ PI3K -‐ AKT) 靶向骨髓瘤的致癌通路(MEK- PI3K - AKT)
Can we cure Multiple Myeloma by 2020? Yes 到2020年我们能治愈多发性骨髓瘤吗?能
Can we cure Multiple Myeloma by 2020? No 到2020年我们能治愈多发性骨髓瘤吗?不能
How to incorporate the Newest Agents Combo vs Sequence -‐ in Favor of Combo 如何合并使用最新药物:联合 vs 序贯-赞成前者
How to incorporate the Newest Agents Combo vs Sequence -‐ in Favor of Sequence 如何合并使用最新药物:联合 vs 序贯-赞成后者
ROBERT KYLE LECTURE Access to Innovation and Quality of Care in the Context of Economic Constraints: a Challenge for Healthcare ROBERT KYLE 讲座:经济紧缩环境下的创新和护理质量:医疗行业的挑战
Monoclonal Gammopathy of Undetermined Significance 意义未明的单克隆丙种球蛋白病
Primary Plasma Cell Leukemia 原发性浆细胞白血病
Amyloid Light-chain Amyloidosis 轻链淀粉样变性
Waldenström Macroglobulinemia Waldenstrom巨球蛋白血症
How to introduce Technology Assessment in Clinical Studies 临床研究中如何引进技术评估
OP-002 Geneme-scale CRISPR-Cas 9 Knockout Studies to characterize the Mechanisms of Myeloma Cell Treatment Resistance OP-002 基因组范围CRISPR-Cas9基因敲除研究以描述骨髓瘤细胞治疗抵抗机制
OP-003 Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) (KRd) combined with Autologous StemSell Transplant (ASCT) shows Emproved Efficacy compared with KRd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM) OP-003 卡非佐米、来那度胺和地塞米松(KRd)联合自体干细胞移植(ASCT)治疗新诊断多发性骨髓瘤患者疗效优于KRd不联合ASCT
OP-004 Early Mortality in Elderly Patients with Newly Diagnosed Multiple Myeloma Treated with Novel Agents OP-004 接受新药治疗的老年新诊断多发性骨髓瘤患者的早期死亡率
OP-005 Ribosomal dysfunction in AL amyloidosis: Gene Expression Study (NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Dexamethasone (DEX) in Patients with Relapsed and Refractory Multiple Myeloma (MM); OP-005 泊马度胺、Marizomib和地塞米松治疗难治/复发多发性骨髓瘤的1期、多中心、开放标签、剂量递增联合试验(NCT02103335):NPI-0052-107研究的初步结果
OP-006 The Genomic and Transcriptional Landscape of Waldenström’s Macroglobulinemia Impacts Disease Presentation, Overall Survival and Therapeutic Response Study NPI-0052-107 Preliminary Results OP-006 Waldenström’s巨球蛋白血症的基因组和转录特征影响疾病表现、总生存率和治疗反应
精选课题专家点评 针对IWM 2015的精选课题,特邀请国内血液病领域专家邱录贵教授、侯健教授、蔡真教授、路瑾教授等进行精彩点评。